期刊文献+

小剂量抗CD_3单克隆抗体治疗肾移植术后早期急性排斥反应的临床研究 被引量:1

Clinical research of using low-dose monoclonal antibody-CD_3 (OKT_3 )on treatment of early acute graft rejection episodes after kidney transplantation
下载PDF
导出
摘要 目的探讨应用小剂量抗CD3单克隆抗体(OKT3)治疗肾移植术后早期急性排斥反应的效果和安全性。方法将33例发生早期急性排斥反应的肾移植病人分为两组,A组16例(OKT35mg/d);B组17例(OKT32.5mg/d)。观察排斥反应逆转情况及感染的发生率。结果A组13例(81.25%)急性排斥反应逆转,移植肾功能恢复正常;1例移植肾自发性破裂行移植肾摘除术,2例移植肾失功恢复血液透析。B组15例(88.24%)急性排斥反应逆转,移植肾功能恢复正常;1例移植肾自发性破裂行移植肾摘除术,1例移植肾失功恢复血液透析。两组排斥反应逆转率无显著性差异(P>0.05)。A组合并感染43.75%,B组5.88%;两组比较有显著性差异(P<0.05)。结论小剂量OKT3治疗肾移植术后早期急性排斥反应的效果良好,并发症少,且费用较低。 Objective:To investigate the effect and reliability of using low-dose OKT3on the treatment of early acute graft rejection episodes after renal transplantation.Methods:33patients with early acute graft rejection episodes were randomly divided into two groups:group A(n=16)receiving OKT 3 5mg/d;group B(n=17)receiving OKT 3 2.5mg/d.It was observational to acute graft rejection reverse rate and occurrence rate of infection.Results:Acute graft rejection were reversed and the recovery normal of graft function81.25%in group A and88.24%in group B,but no significant difference(P>0.05).Group A and group B had one case the graft was eventually re-moved because of spontaneous rupture.Two cases in group A and one case in group B occurred early graft function failures to recover the blood dialysis.A significant difference in combination of infection was seen between group A and group B[43.75%and5.88%,P<0.05].Conclusions:Low-dose OKT 3 on the treatment of early acute graft re-jection episodes is good,and the complications is little,and the expenses is lower.
出处 《中国现代医学杂志》 CAS CSCD 2004年第21期72-74,共3页 China Journal of Modern Medicine
关键词 抗体 单克隆 肾脏移植 移植物排斥 antibodies monoclonal kidney transplantation graft rejection
  • 相关文献

参考文献6

  • 1D'Souza R J, Kwan JT, Chang R, et al. OKT3 in renal allografts:survival and complications [J]. Clin-Nephrol, 1999, 51 (4):257-258.
  • 2Oh HK, Provenzano R, Tayeb J, et al. Two low-dose OKT3 induction regimens following renal transplantation-clinical experience at a single center[J]. Clin-Transplant. 1998, 12(4): 343-7.
  • 3Machado PG, Tedesco HS, Silva RG, et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation[J]. Transplant-Proc,2002, 34(1): 104.
  • 4Mariat C, Alamartine E, Diab N, et al. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients[J]. Transpl-Int, 1998, 11(3): 231-236.
  • 5Carvalho MF, Adoni T, Saggioro FP, et al. Effectiveness of short-term OKT3 therapy in the treatment of steroid-resistant renal allograft rejection[J]. Transplant-Proc, 1998, 30(6): 2876-2877.
  • 6Flechner SM, Goldfarb DA, Fairchild R, et al. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants[J]. Transplantation, 2000, 69(11): 2374-2381.

同被引文献30

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部